Search

Displaying results 3381 - 3390 of 6076 in total
  1. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

    Categories: Drugs for Obstructive Airway Diseases
  2. Drug

    Becocalcidiol

    go.drugbank.com/drugs/DB04891
    Investigational

    Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

  3. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  4. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    However, there currently are no clinical indications for preferential use of ridogrel over aspirin. … Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  5. Drug

    Silicon dioxide

    go.drugbank.com/drugs/DB11132
    Approved

    Silicon dioxide, or silica, is an oxide of silicon with the chemical formula SiO2. It is found in nature as agate, amethyst, chalcedony, cristobalite, flint, sand, QUARTZ, and tridymite as transparent and tasteless crystals. Inhalation o...

    Mixtures: Zenni Tooth for Sensitive Tooth
  6. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  9. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  10. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]